On September 15, 2019, MAPS responded to the U.S. Food and Drug Administration’s (FDA) continued clinical hold with Protocol A3V1 and agreed to all.
On September 15, 2019, MAPS responded to the U.S. Food and Drug Administration’s (FDA) continued clinical hold with Protocol A3V1 and agreed to all.